. 2023 Aug 2;12(9):e230059. doi: 10.1530/EC-23-0059
This work is licensed under a Table 1.
Characteristics of 41 patients with PAI enrolled into the study.
| Whole cohort (n = 41) | AD (n = 24) | SW-CAH (n = 17) | |
|---|---|---|---|
| Age (years) | 39 (27–56) | 50 (33–71) | 31 (26–37) |
| Male % (n) | 61 (25) | 62 (15) | 59 (10) |
| Female % (n) | 39 (16) | 38 (9) | 41 (7) |
| Total daily MC dose (μg/day) | 100 (50–200) | 50 (50–150) | 200 (125–200) |
| Non-adherent to MC % (n) | 12 (5) | 8 (2) | 18 (3) |
| Total daily GC dose (mg/day, HCeq) | 23 (20–32) | 22.5 (18–28) | 28 (24–38) |
| Non-adherent to GC % (n) | 29 (12) | 8 (2) | 59 (10) |
| Hydrocortisone % (n) | 66 (27) | 100 (24) | 18 (3) |
| Prednisolone % (n) | 34 (14) | / | 82 (14) |
| BMI (kg/m²) | 26.2 (21.2–30.3) | 25.2 (21.2–29.4) | 29.5 (20.9–33.1) |
| SBP (mmHg) | 120 ± 16 | 116 ± 14 | 126 ± 17 |
| DBP (mmHg) | 72 ± 9 | 72 ± 8 | 72 ± 12 |
| MAP (mmHg) | 88 ± 10 | 86 ± 8 | 90 ± 12 |
| Na⁺ (mmol/L) | 140 (138–142) | 140 (138–143) | 140 (139–141) |
| K⁺ (mmol/L) | 4.1 (3.6–4.6) | 4.5 (3.9–5) | 3.6 (3.4–4) |
| PRC (μIU/mL) | 136.2 (42.8–310.8) | 107.3 (39.8–251.7) | 164.6 (64.2–406.8) |
| 17-OH-progesterone (nmol/L) | / | / | 35.1 (4.0–102.2) |
| Androstenedione (nmol/L) | / | / | 9.6 (1.7–17.5) |
| sFC (pg/mL) | 29.5 (19.5–47.6) | 25.6 (14.5–62.2) | 29.9 (23.1–40.6) |
| uFC (pg/mL) | 127 (49.9–249.5) | 190.5 (50.2–273.7) | 95.6 (48.9–165.5) |
Data are shown as mean ± s.d. or median (IQR) as appropriate for the distribution of data.
AD, Addison’s disease; BMI, body mass index; DBP, diastolic blood pressure; GC, glucocorticoid; HCeq, equivalent dose of hydrocortisone; K+, potassium levels; MAP, mean arterial pressure; MC, mineralocorticoid; Na+, sodium levels; PRC, plasma renin concentration; SBP, systolic blood pressure; sFC, serum fludrocortisone levels; SW-CAH, salt-wasting congenital adrenal hyperplasia; uFC, urinary fludrocortisone levels.